The Two Most Important Things to Keep in Mind<br />By Rev Shark<br />RealMoney.com Contributor<br />7/1/2008 9:06 AM EDT <br /><br />The very greatest things -- great thoughts, discoveries, inventions -- have usually been nurtured in hardship, often pondered over in sorrow, and at length established with difficulty. <br /><br />--Samuel Smiles <br /><br />As we kick off the third quarter, the gloom is so thick you can cut it with a knife. There are simply no positives out there at the moment. Oil prices keep rising as tensions in the Middle East grow, the financial sector continues to struggle with its massive bad debt issues, and pessimism about the state of the worldwide economy is increasing quickly. <br /><br />The good news is that the evaporation of hope and optimism leads to the sort of environment that eventually will give us a tradable bottom. When things are this negative, investors who have been uncertain about selling will be pushed to do so, and that eventually will give us the washout that leads to a low. <br /><br />It's all a matter of timing, and the big problem is that although things are quite negative and gloomy, there hasn't been enough intensity to the negativity to really drive the marginal holders over the brink and induce them to sell. We haven't had any real panic selling to purge the market of some of its poison, and instead we get slow and steady selling that feeds on itself. <br /><br />There are two important things to keep in mind right now. First and foremost, this market is busted and is in a downtrend. There is no way to know how much longer the pain will last and how much lower things might go. Nonetheless, traditional Wall Street is going to keep on urging us to jump in and start buying. The nature of Wall Street advice is that lower prices are always "buying opportunities." <br /><br />I strongly urge you to ignore the advice to anticipate major market turns. There is no reason to believe that the market is going to get healthier soon. The key right now is to protect your precious capital and keep losses to a minimum so you'll be prepared to profit when the trend starts to turn. <br /><br />The second important thing to keep in mind is that the market is probably close to some sort of oversold bounce. Although we haven't had capitulatory-type selling, the mood is bad and the seasonal conditions are ripe for at least a temporary rebound. <br /><br />If you are already positioned defensively and have a short-term time frame, these counter-trend bounces can present some great opportunities. You just have to keep in mind that you are trading and not investing at this point, and that the goal is to get in and get out and not build up big long-term positions. <br /><br />We have a very poor start this morning, and that is probably a good thing as far as setting us up for a potential bounce. If you have been heeding my advice and are already defensively situated this poor open is a good thing. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: VFC +4.7%, SCHN +2.1%, STZ +2.0% (light volume)... Other news: PPHM +14.3% (awarded DTRA contract worth up to $44.4 mln to develop Bavituximab for viral hemorrhagic fevers), CIT +10.1% (agrees to sell Home Lending business), MBLX +8.7% (announces that Mirel Bioplastics is chosen by Labcon for new laboratory liquid handling system), HALO +4.1% (announces that chemophase meets primary endpoint in phase I/IIa clinical trial), IDXX +3.8% (will replace Getty Images in the S&P MidCap 400), FST +3.1% (updates Haynesville/Bossier shale acreage and development plan; 5 Tcfe of additional net unrisked potential identified), CELG +2.6% (still checking), BQI +2.3% (still checking)... Analyst comments: FTE +2.5% (upgraded to Buy at Merrill and coverage resumed with Buy at Goldman - DJ), MIC +2.3% (upgraded to Outperform at Wachovia), TMRK +2.2% (initiated with Buy at Kaufman), SIRI +1.6% (upgraded to Buy at Merrill), LRCX +1.0% (upgraded to Outperform at Credit Suisse).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: QTWW -6.2% (light volume), FO -6.8% (downgraded to Market Perform at Wachovia), MTW -1.5% (Enodis plc agrees to recommend offer from The Manitowoc Co following completion of auction process)... Select metals/mining stocks showing weakness: RTP -5.4%, LMC -4.1%, BBL -3.6%, AU -3.6%, MT -3.4%, GOLD -2.6%, BHP -2.3%... Select European financial names showing weakness with WSJ reporting UBS (-5.6%) sets board overhaul and adopts new governance rules: RBS -4.4%, DB -3.4%, LYG -3.2%, BCS -3.2%, HBC -2.3%... Select solar names trading lower: CSIQ -4.3%, JASO -3.9%, SOLF -3.2%, ESLR -3.0%, STP -3.0%, FSLR -3.0%, TSL -2.9%, SPWR -2.8%, YGE -2.7%... Other news: IFX -10.3% (falls most in five months as takeover talk evaporates - Bloomberg.com), SFD -6.9% (announces the sale of 7.0 mln shares to China's largest agricultural trading and processing co), SUPG -6.3% (comments on preliminary efficacy update on EORTC Phase 3 Trial of Dacogen versus supportive care in patients with myelodysplastic syndromes; reiterates 2008 annual financial guidance), RVBD -6.3% (still checking), TKG -6.1% (trading ex-dividend), HCN -4.5% (still checking), GSK -1.6% (faces US delay on cancer vaccine - FT)... Analyst comments: TKR -3.9% (downgraded to Neutral at Merrill), ALTR -3.6% (downgraded to Underperform at Jefferies), RBN -2.5% (downgraded to Hold from Buy at BB&T), NYX -2.0% (removed from Conviction Buy List at Goldman - Bloomberg), JPM -1.8% (downgraded to In Line from Outperform at Fox Pitt), MF -1.3% (removed from Focus List at JPMorgan).